S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:AGEN

Agenus - AGEN Stock Forecast, Price & News

$2.56
-0.05 (-1.92%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.37
$2.66
50-Day Range
$1.30
$2.89
52-Week Range
$1.25
$6.79
Volume
5.12 million shs
Average Volume
4.58 million shs
Market Capitalization
$724.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Agenus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
329.7% Upside
$11.00 Price Target
Short Interest
Healthy
5.33% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.58mentions of Agenus in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.89) to ($0.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

126th out of 1,098 stocks

Biological Products, Except Diagnostic Industry

18th out of 174 stocks

AGEN stock logo

About Agenus (NASDAQ:AGEN) Stock

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Analyst Ratings Changes

Separately, TheStreet downgraded shares of Agenus from a "c-" rating to a "d" rating in a research note on Friday, May 27th.

Agenus Stock Performance

NASDAQ:AGEN opened at $2.61 on Tuesday. The firm's 50 day moving average price is $2.18 and its 200-day moving average price is $2.29. Agenus has a 52-week low of $1.25 and a 52-week high of $6.79. The company has a market cap of $738.26 million, a PE ratio of -26.10 and a beta of 1.21.

Agenus (NASDAQ:AGEN - Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.10. The business had revenue of $25.94 million for the quarter, compared to the consensus estimate of $17.35 million. During the same quarter in the prior year, the business posted ($0.27) earnings per share. On average, analysts forecast that Agenus will post -0.89 earnings per share for the current fiscal year.

Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

AGEN Stock News Headlines

Form 8-K AGENUS INC For: Aug 09 - StreetInsider.com
Agenus (AGEN) Set to Announce Quarterly Earnings on Tuesday
Agenus to Participate at BTIG Biotechnology Conference
Why Shares of Agenus Inc. Rose 10.1% on Tuesday
Agenus Inc - Stock Quote AGEN
Agenus (NASDAQ:AGEN) Trading 4% Higher
3 Amazing Stocks Under $10
See More Headlines
Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

AGEN Company Calendar

Last Earnings
11/09/2021
Today
8/09/2022
Next Earnings (Confirmed)
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AGEN
CUSIP
00847G70
Employees
441
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+329.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-23,930,000.00
Pretax Margin
-8.04%

Debt

Sales & Book Value

Annual Sales
$295.67 million
Book Value
$0.19 per share

Miscellaneous

Free Float
269,282,000
Market Cap
$724.12 million
Optionable
Optionable
Beta
1.21

Key Executives

  • Dr. Garo H. Armen Ph.D. (Age 69)
    Founder, Exec. Chairman & CEO
    Comp: $1.28M
  • Ms. Christine M. Klaskin (Age 56)
    VP of Fin., Principal Financial Officer & Principal Accounting Officer
    Comp: $360.51k
  • Dr. Steven J. O'Day M.D. (Age 60)
    Ph.D., Chief Medical Officer
    Comp: $1.44M
  • Dr. Jennifer S. Buell Ph.D. (Age 47)
    Pres & CEO of MiNK Therapeutics
    Comp: $917.25k
  • Craig Winter
    Chief Information Officer
  • Regina Grebla Ph.D.
    VP of Investor Relations & Communications
  • Mr. Ethan Lovell (Age 55)
    Chief External Affairs & Communications Officer
  • Ms. Tracy Mazza Clemente
    Chief People Officer
  • John Castle
    Head of Translational Medicine & Bioinformatics
  • Ms. Julie DeSander
    Chief Bus. Officer













AGEN Stock - Frequently Asked Questions

Should I buy or sell Agenus stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AGEN shares.
View AGEN analyst ratings
or view top-rated stocks.

What is Agenus' stock price forecast for 2022?

2 analysts have issued 12-month price objectives for Agenus' stock. Their AGEN share price forecasts range from $8.00 to $14.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 341.8% from the stock's current price.
View analysts price targets for AGEN
or view top-rated stocks among Wall Street analysts.

How has Agenus' stock price performed in 2022?

Agenus' stock was trading at $3.22 at the beginning of 2022. Since then, AGEN shares have decreased by 22.7% and is now trading at $2.49.
View the best growth stocks for 2022 here
.

When is Agenus' next earnings date?

Agenus is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our AGEN earnings forecast
.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) issued its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.46 by $0.23. The biotechnology company had revenue of $252.95 million for the quarter, compared to analysts' expectations of $183.11 million. During the same period last year, the company posted ($0.28) earnings per share.

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus Chief Executive Officer Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among the company's employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agenus own?

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by many different institutional and retail investors. Top institutional investors include Morgan Jess S & Co. Inc. (0.47%), Los Angeles Capital Management LLC (0.29%), Cardinal Strategic Wealth Guidance (0.22%), Swiss National Bank (0.19%), Strs Ohio (0.13%) and Values First Advisors Inc. (0.08%). Insiders that own company stock include Agenus Inc, Christine M Klaskin, Corp Incyte, Garo H Armen and Steven J O'day.
View institutional ownership trends
.

How do I buy shares of Agenus?

Shares of AGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $2.49.

How much money does Agenus make?

Agenus (NASDAQ:AGEN) has a market capitalization of $704.32 million and generates $295.67 million in revenue each year. The biotechnology company earns $-23,930,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis.

How many employees does Agenus have?

Agenus employs 441 workers across the globe.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The official website for the company is agenusbio.com. The biotechnology company can be reached via phone at (781) 674-4400, via email at investor@agenusbio.com, or via fax at 781-674-4200.

This page (NASDAQ:AGEN) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.